Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

Masahiko Shibata; Kotaro Nanno; Daigo Yoshimori; Takahiro Nakajima; Makoto Takada; Takashi Yazawa; Kousaku Mimura; Norio Inoue; Takafumi Watanabe; Kazunoshin Tachibana; Satoshi Muto; Tomoyuki Momma; Yoshiyuki Suzuki; Koji Kono; Shungo Endo; Seiichi Takenoshita

doi:10.18632/oncotarget.28303

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

Masahiko Shibata _, Kotaro Nanno, Daigo Yoshimori, Takahiro Nakajima, Makoto Takada, Takashi Yazawa, Kousaku Mimura, Norio Inoue, Takafumi Watanabe, Kazunoshin Tachibana, Satoshi Muto, Tomoyuki Momma, Yoshiyuki Suzuki, Koji Kono, Shungo Endo and Seiichi Takenoshita

PDF | Full Text | How to cite | Press Release

Oncotarget. 2022; 13:1273-1285. https://doi.org/10.18632/oncotarget.28303

Metrics: PDF 1447 views | Full Text 2994 views | ?

Abstract

Masahiko Shibata1^,2^,3^,4, Kotaro Nanno2^,5, Daigo Yoshimori2^,5, Takahiro Nakajima2^,3, Makoto Takada4^,6, Takashi Yazawa2^,3^,4, Kousaku Mimura3, Norio Inoue2^,3^,4, Takafumi Watanabe7, Kazunoshin Tachibana8, Satoshi Muto9, Tomoyuki Momma3^,4, Yoshiyuki Suzuki1^,4^,10, Koji Kono1^,3^,4, Shungo Endo11 and Seiichi Takenoshita12

1 Department of Comprehensive Cancer Treatment and Research at Aizu, Fukushima Medical University, Fukushima, Japan

2 Department of Surgery, Cancer Treatment Center, Aizu Chuo Hospital, Fukushima, Japan

3 Department of Gastrointestinal Tract Surgery, Fukushima Medical University, Fukushima, Japan

4 Aizu Oncology Consortium, Fukushima, Japan

5 Department of Surgery, Nippon Medical School, Tokyo, Japan

6 Department of Surgery, Bange Kousei General Hospital, Fukushima, Japan

7 Department of Obstetrics and Gynecology, Fukushima Medical University, Fukushima, Japan

8 Department of Breast Surgery, Fukushima Medical University, Fukushima, Japan

9 Department of Chest Surgery, Fukushima Medical University, Fukushima, Japan

10 Department of Radiation Oncology, Fukushima Medical University, Fukushima, Japan

11 Department of Colorectoanal Surgery, Aizu Medical Center, Fukushima Medical University, Fukushima, Japan

12 Fukushima Medical University, Fukushima, Japan

Correspondence to:

Masahiko Shibata,

email:

[email protected]

Keywords: MDSC; immunosuppression; Treg; TAM; cancer

Received: September 02, 2022 Accepted: October 20, 2022 Published: November 17, 2022

Copyright: © 2022 Shibata et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Although cancer immunotherapy using immune checkpoint inhibitors (ICIs) has been recognized as one of the major treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess various strong immunosuppressive activities involving multiple immunocompetent cells that are significantly accumulated in patients who did not respond well to cancer immunotherapies. We reviewed the perspective of MDSCs with emerging evidence in this review.

Many studies on MDSCs were performed in malignant diseases. Substantial studies on the participation of MDSCs on non-malignant diseases such as chronic infection and autoimmune diseases, and physiological roles in obesity, aging, pregnancy and neonates have yet to be reported. With the growing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being investigated, some of which have been used in clinical trials. More studies are required in order to develop more effective strategies against MDSCs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28303

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more

Abstract